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Abstract: 
Background: Detailed information about lung cancer patients requiring 
admission to intensive care units (ICU) is mostly restricted to single center 
studies. Our aim was to evaluate the clinical characteristics and outcomes 
of lung cancer patients admitted to ICUs.  
Patients and Methods: Prospective multicenter study in 449 patients with 
lung cancer (small-cell, n=55; non-small-cell, n=394) admitted to 22 ICUs 
in six countries in Europe and South America during 2011. Multivariate Cox 
proportional hazards frailty models were built to identify characteristics 
associated with 30-day and 6-month mortality.  
Results: Most of the patients (71%) had newly diagnosed cancer. Cancer-
related complications occurred in 56% of patients; the most common was 
tumoral airway involvement (26%). Ventilatory support was required in 
53% of patients. Overall hospital, 30-day and 6-month mortality rates 
were 39%, 41% and 55%, respectively. After adjustment for type of 
admission and early treatment-limitation decisions, determinants of 
mortality were organ dysfunction severity, poor performance status (PS), 
recurrent/progressive cancer, and cancer-related complications. Mortality 
rates were far lower in the patient subset with non-recurrent/progressive 
cancer and a good PS, even those with sepsis, multiple organ dysfunctions, 
and need for ventilatory support. Mortality was also lower in high-volume 
centers. Poor PS predicted failure to receive the initially planned cancer 
treatment after hospital discharge.  
Conclusions: ICU admission was associated with meaningful survival in 
lung cancer patients with good PS and non-recurrent/progressive disease. 
Conversely, mortality rates were very high in patients with intractable 
disease and poor PS. In this subgroup, palliative care may be the best 
option.  
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ABSTRACT (248 words) 
 
Background: Detailed information about lung cancer patients requiring admission to 
intensive care units (ICU) is mostly restricted to single center studies. Our aim was to 
evaluate the clinical characteristics and outcomes of lung cancer patients admitted to 
ICUs. 
Patients and Methods: Prospective multicenter study in 449 patients with lung cancer 
(small-cell, n=55; non-small-cell, n=394) admitted to 22 ICUs in six countries in 
Europe and South America during 2011. Multivariate Cox proportional hazards frailty 
models were built to identify characteristics associated with 30-day and 6-month 
mortality. 
Results: Most of the patients (71%) had newly diagnosed cancer. Cancer-related 
complications occurred in 56% of patients; the most common was tumoral airway 
involvement (26%). Ventilatory support was required in 53% of patients. Overall 
hospital, 30-day and 6-month mortality rates were 39%, 41% and 55%, respectively. 
After adjustment for type of admission and early treatment-limitation decisions, 
determinants of mortality were organ dysfunction severity, poor performance status 
(PS), recurrent/progressive cancer, and cancer-related complications. Mortality rates 
were far lower in the patient subset with non-recurrent/progressive cancer and a good 
PS, even those with sepsis, multiple organ dysfunctions, and need for ventilatory 
support. Mortality was also lower in high-volume centers. Poor PS predicted failure to 
receive the initially planned cancer treatment after hospital discharge.  
Conclusions: ICU admission was associated with meaningful survival in lung cancer 
patients with good PS and non-recurrent/progressive disease. Conversely, mortality 
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rates were very high in patients with intractable disease and poor PS. In this subgroup, 
palliative care may be the best option. 
 
Key words: Lung Cancer, intensive care, cancer-related complications, multicenter 
study, outcome. 
 
Abbreviation List 
Confidence interval - CI 
Electronic Supplementary Material - ESM 
Eastern Cooperative Oncology Group - ECOG 
Intensive care unit - ICU 
Interquartile range – IQR 
Length of stay - LOS 
Non-small-cell lung cancer - NSCLC  
Organ failure - OF 
Performance status – PS  
Renal replacement therapy - RRT 
Small-cell lung cancer - SCLC  
Sequential Organ Failure Assessment – SOFA 
Simplified Acute Physiology Score - SAPS 
Surveillance, Epidemiology, and End Results - SEER 
Treatment limitation decisions – TLD 
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INTRODUCTION 
 
Lung cancer is the most frequently diagnosed malignancy and the leading cause 
of cancer-related mortality worldwide.[1] Despite advances in the management, overall 
long-term survival remains poor particularly in patients with non-resectable or 
metastatic tumors.[2] Nevertheless, complete recovery or prolonged survival can be 
achieved in some patients with non-small-cell lung cancer (NSCLC).[3-5] 
 Lung cancer patients account for approximately 8% of all ICU admissions of 
patients with malignancies and 27% of those with solid cancer.[6,7] Over the last 
decade, improvements in ICU outcomes of these patients were documented in studies 
performed worldwide.[8-13] However, lung cancer patients are usually perceived as 
having substantially worse ICU outcomes compared to other cancer patients. Therefore, 
ICU admission for life-threatening events is still widely viewed as unlikely to benefit 
these patients, particularly when ventilatory support is needed.[14,15] 
The available information about lung cancer patients requiring ICU admission 
comes chiefly from single-center studies reporting ICU or hospital mortality rates in 
small groups of patients.[8-15] Recently, however, two studies used administrative 
databases to evaluate the outcomes of lung cancer patients admitted to the ICU.[16,17] 
Nevertheless, both were conducted in a single country (the USA) and did not provide 
detailed information about the reasons for ICU admission, characteristics of the lung 
malignancies, or anticancer treatments. Moreover, data on the clinical course and 
anticancer treatment continuation rates in ICU survivors are very limited.[10] 
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Here, our objective was to study a large population of critically ill patients with 
lung cancer admitted to European or South American ICUs, in order to describe their 
clinical characteristics and outcomes and to identify factors associated with short- and 
long-term mortality. 
 
 
PATIENTS AND METHODS 
 
Design and Setting 
This prospective multinational cohort study was conducted in 22 ICUs in 
Argentina (n=1), Brazil (n=5), Chile (n=1), France (n=10), the United Kingdom (n=2), 
and Uruguay (n=3) throughout 2011. All participating investigators and centers are 
listed in the eAppendix of the Electronic Supplementary Material (ESM). The study was 
observational, with all clinical decisions left to the attending physicians. The study was 
approved initially by the Brazilian National Ethics Committee (approval number 
CONEP 15.790) and subsequently by local and national ethics committees in the 
participating centers and countries. In the few centers that required informed consent for 
the study, written informed consent was obtained from each patient or legal 
representative before study inclusion. 
 
Patient Selection, Data Collection, and Definitions 
Consecutive patients aged ≥18 years with a diagnosis of lung cancer requiring 
ICU admission at the participating centers were evaluated. We did not include patients 
with ICU stays shorter than <24 h, complete cancer remission for more than 5 years, 
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previous ICU admission, malignancies other than primary lung cancer, or unwillingness 
to participate in the study. 
Demographic, clinical, and laboratory data collected included hospital location 
before ICU, reason for ICU admission, Eastern Cooperative Oncology Group 
performance status (ECOG-PS),[18] Simplified Acute Physiology Score (SAPS) II,[19] 
Sequential Organ Failure Assessment (SOFA) score,[20] and comorbidities with 
determination of the Charlson Comorbidity Index [21]. The use during the ICU stay of 
ventilatory support (invasive and non-invasive mechanical ventilation) for longer than 
24h, vasopressors, and renal replacement therapy (RRT) were recorded. The following 
cancer-related data were collected: histological type, cancer stage, anticancer treatments 
(radiation, chemotherapy, and surgical resection), cancer-related complications, and 
cancer status (newly diagnosed, recurrent/progressive, or in remission). In patients with 
non-small cell lung cancer (NSCLC), disease stage was evaluated using the TNM 
classification, with limited disease defined as stage I-IIIa and extensive disease as stage 
IIIb-IV. Lung cancer was considered a reason for ventilatory support in patients with 
bilateral lung involvement, carcinomatous lymphangitis, or tumor masses causing 
airway obstruction.[8] All patients were followed up until hospital discharge. In 
addition, hospital survivors were followed up until 6 months after ICU admission. 
 
Data entry and processing 
Data were collected using a web-based standardized electronic case report form 
developed specifically for the study. All investigators and research coordinators had 
access to the website, which contained all the study documents including a manual 
detailing the data-collection requirements and definitions. The investigators could 
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contact the steering committee members and country coordinators by telephone and 
email if needed. Local investigators completed a form reporting the ICU and hospital 
characteristics and were responsible for supervising data collection and checking data 
completeness and quality. Data were screened by a single investigator (MS) for missing 
information, implausible and outlying values, errors in logic, and lack of detail; this 
investigator contacted the local investigators as needed to resolve these issues. 
 
Statistical Analysis 
Continuous variables were reported as mean±SD or median (25%-75% 
interquartile range, IQR). Patients were managed in different centers, giving the data a 
multilevel structure. We used a shared frailty model to identify factors associated with 
death (PROC PHREG SAS 9.3). Risk factors for 30-day and 6-month mortality were 
estimated using a Cox proportional hazards frailty model. The center effect was handled 
as a random effect in the model. Variables included in the multivariate model were 
those yielding P values <0.25 in univariate frailty models. Center- and patient-related 
variables yielding P values <0.05 in the multivariate context were kept in the model. 
Survival curves were plotted using the Kaplan-Meier method. All statistical analyses 
were performed using SAS 9.3 (SAS Institute, Cary, NC, USA). P values less than 0.05 
were considered significant. 
 
 
RESULTS 
 
Characteristics of participating hospitals and ICUs 
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 The main characteristics of the 22 participating hospitals and ICUs are listed in 
Table 1. Lung cancer patients accounted for 3.5% (716/20,351; range: 0.4%-17.8%) of 
all ICU admissions during the study period. The median number of patients admitted 
per center during the study year was 18 (IQR, 7-50; range, 3-138) and the median 
number of patients included in the study per center was 15 (IQR, 6-29; range, 2-69). 
The study flowchart is given in eFigure 1 of the ESM. 
 
Patient characteristics 
Tables 2 and 3 report the main characteristics of the 449 patients included in the 
study. The main reasons for ICU admission were postoperative complications (41%), 
acute respiratory failure (23%) and sepsis (21%). 
There were 394 (88%) patients with NSCLC and 55 (12%) patients with SCLC. 
The most frequent histological type was adenocarcinoma (57%). Median time since 
cancer diagnosis was 74 (IQR, 22-185) days. Previous anticancer treatments included 
surgical resection (17%), radiation therapy (22%), and single-drug or combination 
chemotherapy (42%). More than half the patients had cancer-related complications at 
ICU admission, with the most common being airway compromise by the tumor (Table 
3). 
 
Outcome analysis 
The overall ICU, hospital, 30-day and 6-month mortality rates were 28%, 39%, 
41% and 55%, respectively. Treatment-limitation decisions (TLD) were taken in 138 
(31%) patients, after a median of 4 (1-11) days in the ICU admission, and 110 (80%) of 
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these patients died in the hospital. Of note, TLD were implemented on the first ICU day 
in 38 (8%) patients. Table 2 compares the survivors and non-survivors.  
The results of the univariate analyses to identify factors associated with 30-day 
and 6-month mortality are reported in eTables 1 and 2 of the ESM. Center-related 
variables assessed by univariate analysis were type of hospital, number of hospital beds, 
type of ICU, and percentage of all ICU admissions contributed by lung cancer patients 
during the study period. Patient-related data were age, type of ICU admission, hospital 
length of stay before ICU admission, SOFA score, Charlson index, PS, TLD on the first 
ICU day, type of lung cancer, cancer stage and status, and presence of cancer-related 
complications. 
Table 4 reports the results of the multivariate analyses. After adjustment for type 
of admission and TLD taken on the first ICU day, the main determinants of 30-day and 
6-month mortality were higher SOFA scores, poor PS, recurrent/progressive cancer, and 
presence of cancer-related complications (airway compromise, deep vein thrombosis, or 
superior vena cava syndrome). Admission to high-volume centers was associated with 
lower mortality, particularly at 30 days. Histological type of cancer was not associated 
with mortality. Figure 2 shows mortality rates according to the main combinations of 
PS, cancer status, and treatment requirements. Survival curves for all patients and 
subsets defined based on prognostic factors are provided in the ESM (eFigures 2a to 2f). 
 
Emergency anticancer treatments during the ICU stay 
 Twenty-five (NSCLC=14; SCLC=11) patients received emergency anticancer 
treatments (chemotherapy, n==20; radiation therapy, n=4; both, n=1) in the ICU. In 
17/25 (68%) patients, the reason for emergency anticancer treatment was extensive 
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disease causing severe acute complications being the most frequent airway compromise 
(56%) and large pleural/pericardial effusion (44%). No severe treatment-related 
complications occurred during the ICU stay. ICU, hospital, and 6-month mortality rates 
in these 25 patients were 36%, 44%, and 68%, respectively. 
 
Picture of hospital survivors 
 Of the 449 patients, 275 were discharged alive from the hospital, 246 (89%) with 
NSCLC and 29 (11%) with SCLC. Among them, 200 (73%) were known to be alive at 
6 months and 72 (26%) had died; vital status was unknown for 3 (1%) patients. Cancer 
recurrence or progression occurred in 53 (26%) hospital survivors. Anticancer 
treatments were recommended to 108 (39%) hospital survivors and administered to 102; 
anticancer treatment was not recommended to 121 (44%) patients and information on 
this item was not available for 46 (17%) patients. In the 102 treated patients, the 
treatments used were variable combinations of surgical resection (7%), radiation 
therapy (34%), and chemotherapy (80%). In 35 (34%) patients, the initial anticancer 
treatment plan required reduction or modification. Post-hospital mortality was non-
significantly lower in the patients given the initial treatment plan than in the other 
patients (17% vs. 32%, P=0.065). Poor PS was the only factor associated with a lower 
probability of receiving the initial treatment plan (odds ratio, 0.20; 95% confidence 
interval, 0.05-0.87; P=0.032). 
 Among the 200 patients alive at 6 months, 142 (71%) were at home, 30 (15%) 
were hospitalized, and 14 (7%) were in hospice care; the location was unknown for 12 
(6%) patients. PS at 6 months was 3-4 in 19 (9.5%) survivors.  
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DISCUSSION 
 
This multinational study obtained prospective data in a large population of lung 
cancer patients admitted to the ICU. Lung cancer patients accounted for 3.5% of all ICU 
admissions. Their mortality rates were comparable to those in unselected cancer patients 
requiring ICU admission in previous multicenter studies.[6,7] Slightly over one-third of 
hospital survivors received anticancer treatments after discharge. Most of 6-month 
survivors were living at home. 
In recent years, several specialized centers reported improved outcomes after 
ICU admission of lung cancer patients.[8-13] Two studies were published recently using 
administrative databases that contained no information on many relevant clinical 
characteristics.[16,17] In contrast to earlier studies, we considered both center- and 
patient-related variables in our assessment of factors potentially associated with 
mortality. After adjustment for medical vs. surgical ICU admission and TLD on the first 
ICU day, in addition to the severity of acute organ dysfunctions, three main factors were 
associated with increased 6-month mortality: poor PS before ICU admission, recurrent 
or progressive cancer, and presence of serious cancer-related complications (airway 
compromise, deep vein thrombosis, or superior vena cava syndrome). PS before ICU 
admission was closely associated with 30-day and 6-month mortality across the range of 
clinical presentations. In addition, a poor PS also predicted inability to receive the initial 
anticancer treatment plan in hospital survivors. Importantly, admission to high-volume 
centers was associated with lower mortality. This effect may be related to experience, 
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closer collaboration between oncologists and intensivists, or more efficient ICU triage 
policies. 
At ICU admission, about half the patients had cancer-related complications, 
some of which required emergency treatment. Thus, 25 patients received emergent 
chemotherapy and/or radiation therapy in the ICU. These treatments were not associated 
with increased mortality or acute toxicities, although their impact on the long term-
outcome is unclear. Hospital and six-month mortality rates of 44% and 68%, 
respectively, in these 25 patients suggest that rescue anticancer treatment started in the 
ICU may be of benefit in highly selected patients. 
Strengths of our study include the large number of patients from different 
countries admitted not only in referral cancer centers, but also in general hospitals. 
Patient recruitment over a single year minimized the possible influence of changes in 
treatment modalities over time. A limitation of our study is that we included patients 
admitted to a convenience sample of centers in six countries. Therefore, our population 
cannot be considered representative of all lung cancer patients admitted to the ICU. In 
addition, we obtained data only for the first 6 months after ICU admission. Information 
on longer-term outcomes is needed. Finally, we did not collect data on quality of life. 
In conclusion, in this multinational study, ICU admission provided substantial 
survival rates in patients with good PS and non-recurrent/progressive disease, including 
those who had severe acute complications such as sepsis, multiple organ failure, and 
need for ventilatory support. In addition, more than a third of the hospital survivors 
received anticancer treatment. PS before ICU admission was associated with both 
mortality and ability to receive optimal anticancer treatment after hospital discharge. On 
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the other hand, mortality rates were very high in patients with intractable disease and 
poor PS. In this subgroup, palliative care may be the best option.[22,23] 
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FIGURE LEGENDS 
 
Figure. ICU (white bars), hospital (gray bars), and 6-month (black bars) mortality rates 
according to clinical presentation in critically ill patients with lung cancer. PS, 
performance status; Ca_Progress, cancer recurrence or progression; Ca_Complic, 
cancer-related complications; MODS, multiple organ dysfunction syndrome; 
Non_Ca_Progress, no recurrence or progression of the cancer; Vent_Supp, ventilatory 
support. 
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Soares et al. Lung Cancer in Critical Care (LUCCA) Study. 1 
Table 1– Characteristics of participating centers (n=22) 
Variables 
n (%) or median 
(IQR) 
Hospital characteristics  
Type of hospital  
     University/affiliated 14 (64%) 
     Private 8 (36%) 
Hospital beds 345 (215 – 723) 
     <200 5 (23%) 
     200-499 8 (36%) 
     >500 9 (41%) 
Hospital facilities  
     Intermediate/step-down unit  15 (68%) 
     Oncology department 22 (100%) 
     Radiation therapy unit 16 (73%) 
     Chemotherapy 20 (91%) 
     Bone marrow transplant unit 16 (73%) 
ICU characteristics  
Type of ICU  
     General 18 (82%) 
     Oncological 4 (18%) 
Closed ICU 19 (86%) 
ICU beds 15 (12 – 20) 
     <10 4 (18%) 
     11-20 13 (59%) 
     >20 5 (23%) 
Persons involved in ICU-admission triage decisions  
     ICU physician 20 (91%) 
     Attending oncologist 9 (41%) 
     ICU nurse 1 (4%) 
     Family/patient 4 (18%) 
ICU admissions of patients with lung cancer in 2011  
% total admissions contributed by patients with lung cancer 
(quartiles) 
a
 
 
     <3% 12 (55%) 
     3% - 5% 4 (18%) 
     5% - 6.7% 3 (14%) 
     >6.7% 2 (9%) 
ICU, intensive care unit; IQR, 25%-75% interquartile range 
a
[ICU admissions of patients with lung cancer (n)/All ICU admissions (n)]·100
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Table 2. Main patient characteristics and comparison of 6-month survivors and nonsurvivors
a,b
 
Variables 
All patients  
(n=449) 
Survivors 
(n=203, 45%) 
Nonsurvivors 
(n=246, 55%) 
P value
c
 
Characteristics at ICU admission     
Age (years) 63.8 ± 11.7 62.7 ± 11.9  64.7 ± 11.6 0.096 
Gender     
     Female 148 (33%) 67 (45%) 81 (55%) 0.986 
     Male 301 (67%) 136 (45%) 165 (55%)  
Type of admission     
     Surgical 182 (41%) 132 (73%) 50 (27%) <10
-4
 
     Medical 267 (59%) 71 (27%) 196 (73%)  
Hospital LOS prior to ICU admission (days) 1 (0-4) 1 (0-2) 2 (0-6) 0.004 
SAPS II (points) 46.1 ± 19.1 36.5 ± 13.9 54.1 ± 19.1 <10
-4
 
SOFA score – First ICU day (points) 5 (3-8) 4 (2-6) 6 (4-11) <10
-4
 
Charlson Comorbidity Index (points) 
d
 0 (0-1) 0 (0-1) 0 (0-1)  
     0-2 414 (92%) 186 (45%) 228 (55%) 0.678 
     >2 35 (8%) 17 (49%) 18 (51%)  
Performance status     
     0-2 379 (84%) 195 (51%) 184 (49%) <10
-4
 
     3-4 70 (16%) 8 (11%) 62 (89%)  
Organ support during ICU stay     
Ventilatory support on day 1 239 (53%) 79 (33%) 160 (67%) <10
-4
 
Vasopressors on day 1 128 (29%) 34 (27%) 94 (73%) <10
-4
 
Dialysis on day 1 20 (4%) 4 (20%) 16 (80%) 0.021 
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Soares et al. Lung Cancer in Critical Care (LUCCA) Study. 3
Table 2. Main patient characteristics and comparison of  6-month survivors and nonsurvivors
a,b
 (continued)
 
Variables 
All patients  
(n=449) 
Survivors 
(n=203, 45%) 
Nonsurvivors 
(n=246, 55%) 
P value 
c
 
Outcome data     
     Treatment-limitation decisions 138 (31%) 8 (6%) 130 (94%) <10
-4
 
     Treatment-limitation decisions on day 1 38 (8%) 3 (8%) 35 (92%) <10
-4
 
     ICU LOS (days) 4 (2-10) 4 (2-7) 6 (3-11) 4·10
-4
 
     Hospital LOS (days) 14 (8-26) 13 (7-22) 16 (8-27) 0.188 
     Survival censoring at 6 months (days) 48 (11-180) - -  
     ICU mortality 126 (28%) - -  
     Hospital mortality 174 (39%) - -  
     30-day mortality 186 (41%) - -  
     Six-month mortality 
b
 246 (55%) - -  
a
Data are mean±SD, median (25%-75% IQR), or n (%). 
b
Survival 6 months after ICU admission. Three (0.7%) patients were lost to follow-up and were censored at hospital discharge. 
c
P values for survivors versus nonsurvivors 
d
Lung cancer was not considered when computing the Charlson Comorbidity Index. 
ICU, intensive care unit; LOS, length of stay; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; SD,  
standard deviation; IQR, interquartile range 
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Table 3. Cancer-related data and comparison of 6-month survivors and nonsurvivors
a
 
Variables 
All patients  
(n=449) 
Survivors 
(n=203, 45%) 
Nonsurvivors 
(n=246, 55%) 
P value
b
 
Type of lung cancer     
     NSCLC 394 (88%) 181 (46) 213 (64)  
          Adenocarcinoma  258 (57%) 118 (46) 140 (54) 0.850 
          Squamous cell 120 (27%) 55 (46) 65 (54)  
          Other 16 (4%) 8 (50) 8 (50)  
     SCLC 55 (12%) 22 (40) 33 (60)  
Cancer stage    <10
-4
 
     Limited 171 (38%) 112 (66) 59 (35)  
     Extensive 278 (62%) 91 (33) 187 (67)  
Cancer status    <10
-4
 
     Controlled/remission 32 (7%) 21 (66) 11 (34)  
     Newly-diagnosed 318 (71%) 160 (50) 158 (50)  
     Recurrence/progression 99 (22%) 22 (22) 77 (78)  
Cancer-related complications at ICU admission 251 (56%) 79 (31) 172 (69) <10
-4
 
     Airway compromise by tumor 116 (26%) 36 (31) 80 (69) 4·10
-4
 
     Chemotherapy and/or radiation toxicity 55 (12%) 14 (25%) 41 (75%) 0.002 
     Deep vein thrombosis 35 (8%) 4 (11%) 31 (89%) <10
-4
 
     Neutropenia 26 (6%) 4 (15%) 22 (85%) 0.002 
     Superior vena cava syndrome 20 (5%) 4 (20) 16 (80) 0.021 
     Intracranial mass effect 21 (5%) 5 (24%) 16 (76%) 0.044 
     Hypercalcemia 7 (2%) 1 (14%) 6 (86%) 0.132 
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Table 3. Cancer-related data and comparison of 6-month survivors and nonsurvivors 
a
 (continued)
 
Variables 
All patients  
(n=449) 
Survivors 
(n=203, 45%) 
Nonsurvivors 
(n=246, 55%) 
P value
b
 
     Spinal cord compression 7 (7%) 0 7 (100%) 0.017 
     Other 67 (15%) 27 (40%) 40 (60%) 0.411 
Emergency anticancer treatments during ICU 
stay
c
 
25 (6%) 7 (28) 18 (72) 0.0752 
     Chemotherapy 21 - -  
     Radiation therapy 5 - -  
a
Survival 6 months after ICU admission. Three (0.7%) patients were lost to follow-up and were censored at hospital discharge. 
b
P values for patients with lung cancer versus other solid tumors 
c
One patient received both chemotherapy and radiation therapy. 
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; ICU, intensive care unit 
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Table 4. Cox proportional hazards frailty models of characteristics associated with 30-day and six-month mortality (n=449)
a
 
               Censored at 30 days               Censored at 6-months 
Variables Hazard Ratio (95%CI) P value Hazard Ratio (95%CI) P value
Type of admission 
     Surgical 1.000 -
     Medical 1.675 (1.113 – 2.521) 0.013 -
SOFA score for all patients (points) 1.112 (1.076 – 1.150) <0.001 -
     SOFA score for medical patientsb - 1.125 (1.093 – 1.159) <0.001
     SOFA score for surgical patients
b
 - 1.090 (1.025 – 1.159) 0.006
Performance status 
     0-2 1.000 1.000
     3-4 2.083 (1.470 – 2.953) <0.001 2.342 (1.680 – 3.265) <0.001
Cancer status according to TLDs on ICU day 1
c
 <0.001 <0.001
     Controlled /remission without TLDs (n=31) 1.000 1.000
     Newly-diagnosed without TLDs (n=294) 2.482 (0.902 – 6.828) 1.484 (0.765 – 2.876)
     Recurrence/progression without TLDs (n=86) 3.690 (1.313 – 10.373) 2.509 (1.261 – 4.994)
     Controlled/remission with TLDs (n=1) 214.077 (20.621 – 2,222.411) 149.678 (15.610 – 1,435.223)
     Newly-diagnosed with TLDs (n=24) 6.589 (2.180 – 19.912) 4.603 (2.067 – 10.251)
     Recurrence/progression with TLDs (n=13) 10.795 (3.421 – 34.071) 6.119 (2.502 – 14.969)
Cancer-related complications at ICU admission 
     Airway compromise by tumor 1.671 (1.208 – 2.313) 0.002 1.541 (1.150 – 2.066) 0.004
     Deep vein thrombosis 1.711 (1.109 – 2.637) 0.015 1.873 (1.244 – 2.822) 0.003
     Superior vena cava syndrome 1.738 (1.006 – 3.000) 0.047 -
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Table 4. Cox proportional hazards frailty models of characteristics associated with 30-day and six-month mortality (n=449)
a
 (continued) 
               Censored at 30 days               Censored at 6-months 
Variables Hazard Ratio (95%CI) P value Hazard Ratio (95%CI) P value
% total admissions contributed by patients with lung 
cancer in 2011d 
0.001 0.026
     <3% 1.000 1.00
     3%-5% 1.053 (0.699-1.585) 1.123 (0.630 – 2.003)
     >5%-6.7% 1.064 (0.704-1.607) 0.955 (0.478 – 1.909)
     >6.7% 0.467 (0.293-0.744) 0.559 (0.307 – 1.017)
a
Survival 6 months after ICU admission. Three (0.7%) patients were lost to follow-up and were censored at hospital discharge. 
b
There was a significant interaction between SOFA scores and type of admission in the model with censoring at 6 months (P=0.009). 
c
There was a significant interaction between cancer status and treatment-limitation decision on ICU day 1 in both models (P=0.002). 
d
[ICU admissions of patients with lung cancer (n)/All ICU admissions (n)]·100 
95%CI, 95% confidence interval; SOFA, Sequential Organ Failure Assessment; TLD, treatment-limitation decision; ICU, intensive care 
unit 
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e-Appendix: LUCCA Study Investigators and Participating Centers 
 
Steering Committee: Márcio Soares, Jorge I. F. Salluh, Jean-François Timsit, Élie Azoulay. 
Argentina: Instituto Medico Especializado Alexander Fleming, Buenos Aires (Célica 
Irrazábal, Pierina Bachetti); Brazil: Instituto Nacional de Câncer, Rio de Janeiro (Vicente C. 
Souza-Dantas, Mauro M. Zamboni, Aureliano Sousa), Hospital A. C. Camargo, São Paulo 
(Bruno F. C. Almeida, Lúcio S. Santos, Pedro Caruso), Fundação Pio XII - Hospital de 
Câncer de Barretos, Barretos (Ulysses V. A. Silva), Hospital Sírio Libanês, São Paulo 
(Luciano C. P. Azevedo, Guilherme P. P. Schettino), Vitória Apart Hospital, Vitória (Cláudio 
Piras, Stéphanie B. Piras, Albano S. M. T. Silva); Chile: Hospital Clinico Universidad de 
Chile, Santiago (Eduado Tobar, Nivia Estuardo); France: Gustave Roussy, Villejuif 
(François Blot, Bruno Raynard), APHP-Hopital Tenon, Paris (Antoine Parrot), Hospices 
Civils de Lyon Centre Hospitalier Lyon Sud, Lyon (Florent Wallet), Institut Mutualiste 
Montsouris, Paris (Christian Lamer), Groupe Hospitalier Pitié Salpêtrière, Paris (Alexandre 
Duguet, Alexandre Demoule, Julie Delemazure, Julien Mayaux, Thomas Similowski), Hôpital 
A. Michallon Chu de Grenoble, Grenoble (Surgical ICU: Michel Durand, Geraldine 
Dessertaine, Pr Jean François Payen; Medical ICU: Anne-Claire Toffart, Jean-François 
Timsit), Hôpital de la Croix-Rousse, Lyon (Gael Bourdin, Claude Guerin), Hôtel Dieu de 
Paris, Paris (Antoine Rabbat; Aurélie Lefebvre), Hopital Saint Louis, Paris (Élie Azoulay); 
United Kingdom: Royal Marsden Hospital, London (Natalie Pattison), Royal Brompton 
NHS Foundation Trust, London (Natalie Pattison); Uruguay: Hospital Maciel, Montevideo 
(Gastón Burghi, Darwin Tejera), Asocianción Española Primera de Socorros Mutuos, 
Montevideo (Darwin Tejera, Gastón Burghi), Hospital de Clínicas, Montevideo (Gastón 
Burghi, Darwin Tejera). 
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eTable 1. Univariate analyses of center-related characteristics associated with 30-day and 6-month mortality (n=449)
a
 
 Censored at 30 days Censored at 6 months 
Variables HR (95%CI) P value  HR (95%CI) P value  
Hospital characteristics     
Type of hospital     
     University/affiliated vs. private 1.140 (0.703-1.847) 0.290 1.272 (0.781-2.074) 0.104 
Hospital beds  0.057  0.020 
     <200 1  1  
     200-499 1.592 (0.857-2.958)  1.778 (0.965-3.277)  
     >500 1.858 (0.962-3.587)  2.020 (1.060-3.850)  
Hospital facilities     
     Intermediate / step down unit 0.930 (0.554-1.562) 0.421 0.999 (0.584-1.707) 0.805 
     Radiation therapy unit  1.279 (0.738-2.214) 0.188 1.177 (0.674-2.058) 0.245 
     Bone marrow transplant unit 1.160 (0.689-1.951) 0.291 1.218 (0.717-2.067) 0.170 
ICU characteristics     
Type of ICU: oncological vs. general 1.117 (0.616-2.024) 0.358 1.022 (0.549-1.903) 0.559 
ICU beds  0.463  0.408 
     <10 1  1  
     11 – 20 1.009 (0.536-1.902)  0.865 (0.453-1.649)  
     >20 1.179 (0.583-2.383)  0.953 (0.458-1.984)  
% admissions of patients with lung cancer in 2011 b  0.004  0.014 
<3% 1  1  
3% to 5% 0.897 (0.560-1.435)  1.011 (0.584-1.752)  
5% to 6.7% 0.693 (0.418-1.150)  0.666 (0.348-1.276)  
> 6.7% 0.432 (0.258-0.726)  0.532 (0.301-0.941)  
ICU, intensive care unit; HR, hazard ratio; CI, confidence interval 
a Three (0.7%) patients were lost to follow-up and were censored at hospital discharge. 
b [ICU admissions of patients with lung cancer (n) /All ICU admissions (n)]·100 
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eTable 2. Univariate analyses of patient-related characteristics associated with 30-day and 6-month mortality (n=449)
a
 
 Censored at 30 days Censored at six months 
Variables HR (95%CI) P value  HR (95%CI) P value  
Characteristics at ICU admission      
Age (years)  0.895  0.893 
     <57 1  1  
     57-64 0.898 (0.592-1.360)  1.069 (0.737-1.550)  
     65-71 0.878 (0.569-1.357)  1.052 (0.716-1.547)  
     >71 0.992 (0.661-1.490)  1.151 (0.797-1.663)  
Male vs. Female 0.997 (0.732-1.359) 0.986 1.020 (0.777-1.339) 0.883 
Medical vs. surgical admission 3.610 (2.478-5.260) <0.001 4.163 (2.982-5.813) <0.001 
Hospital LOS before ICU admission (days)  0.006  2.10-4 
     0 1  1  
     0-3 0.850 (0.577-1.253)  0.747 (0.527-1.058)  
     ≥4 1.506 (1.041-2.177)  1.491 (1.076-2.065)  
SAPS II (per point) 1.037 (1.030-1.045) <0.001 1.039 (1.032-1.046) <0.0014 
SOFA score (per point) 1.123 (1.088-1.159) <0.001 1.120 (1.089-1.153) <0.001 
Charlson Comorbidity Index: >2 vs. 0-2 0.803 (0.449-1.435) 0.447 0.856 (0.519-1.411) 0.529 
Performance status: 3-4 vs. 0-2 3.267 (2.325-4.592) <0.001 3.593 (2.613-4.941) <0.001 
Organ support on ICU day 1     
Mechanical ventilation (IMV + NIV) 2.747 (1.987-3.797) <0.001 2.340 (1.776-3.083) <0.001 
Vasopressors  2.254 (1.666-3.051) <0.001 2.132 (1.625-2.796) <0.001 
Dialysis  2.145 (1.183-3.890) 0.011 2.212 (1.287-3.802) 0.004 
Treatment limitation decisions on day 1 4.213 (2.755-6.443) <0.001 3.902 (2.612-5.828) <0.001 
a Three (0.7%) patients were lost to follow-up and were censored at hospital discharge. 
HR, hazard ratio; CI, confidence interval; ICU, intensive care unit; LOS, length of stay; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure 
Assessment; IMV, invasive mechanical ventilation; NIV, noninvasive ventilation; TLD, treatment-limitation decisions 
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eTable 2. Univariate analyses of patient-related characteristics associated with 30-day and 6-month mortality (n=449)
a
 
 Censored at 30 days Censored at six months 
Variables HR (95%CI) P value  HR (95%CI) P value  
Cancer-related characteristics     
Type of lung cancer  0.179  0.602 
     Adenocarcicnoma 1  1  
     Squamous-cell 1.058 (0.748-1.498)  0.977 (0.721-1.323)  
     Other 1.268 (0.581-2.770)  1.019 (0.491-2.114)  
     SCLC 1.595 (1.043-2.440)  1.289 (0.868-1.913)  
Extensive disease 2.652 (1.861-3.777) <0.001 2.496 (1.845-3.377) <0.001 
Cancer status  <0.001  <0.001 
     Controlled/remission 1  1  
     Uncontrolled, newly-diagnosed 3.054 (1.236-7.545)  1.998 (1.069-3.732)  
     Uncontrolled, recurrence/progression 5.651 (2.243-14.233)  3.936 (2.060-7.519)  
Cancer-related complications at ICU admission  2.727 (1.950-3.815) <0.001 2.533 (1.903-3.371) <0.001 
     Airway compromise by cancer  2.090 (1.535-2.845) <0.001 1.933 (1.462-2.556) <0.001 
     Chemotherapy and/or radiation toxicity  1.747 (1.188-2.571) 0.004 1.633 (1.147-2.326) 0.006 
     Deep vein thrombosis  2.503 (1.619-3.869) <0.001 2.654 (1.778-3.963) <0.001 
     Neutropenia  1.575 (0.929-2.672) 0.088 1.817 (1.150-2.871) 0.010 
     Superior vena cava syndrome  2.513 (1.463-4.317) 8.10-4 2.185 (1.296-3.683) 0.003 
     Intracranial mass effect  1.265 (0.668-2.393) 0.453 1.414 (0.823-2.431) 0.198 
Emergent anticancer treatments during ICU stay 0.971 (0.534-1.766) 0.919 1.134 (0.690-1.864) 0.610 
a Three (0.7%) patients were lost to follow-up and were censored at hospital discharge. 
HR, hazard ratio; CI, confidence interval; SCLC, small cell lung cancer; ICU, intensive care unit 
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eFigure 1. Study flowchart 
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eFigure 2a. Survival curve for all patients (n=449) 
 
 
 
 
 
 
n at risk d0 d30 d60 d90 d120 d150 d180 
 449 260 234 219 208 203 200 
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eFigure 2b. Survival according to proportion of ICU patients with lung cancer among all ICU 
admissions in 2011 
 
 
 
 
n at risk d0 d30 d60 d90 d120 d150 d180 
>6.7% 112 81 75 71 67 65 64 
5 to 6.7% 132 77 71 69 68 67 65 
3 to 5% 110 58 48 43 41 39 39 
<3% 95 44 40 36 32 32 32 
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eFigure 2c. Survival according to performance status. 
 
 
  
 
 
 
n at risk d0 d30 d60 d90 d120 d150 d180 
PS 0-2 379 244 222 210 200 196 193 
PS 3-4 70 16 12 9 8 7 7 
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eFigure 2d. Survival according to cancer stage. 
 
 
 
 
  
 
n at risk d0 d30 d60 d90 d120 d150 d180 
Localised  171 129 122 118 112 111 111 
Extensive 278 131 112 101 96 92 89 
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eFigure 2e. Survival according to cancer status. 
 
 
 
 
 
 
 
 
n at risk d0 d30 d60 d90 d120 d150 d180 
Controlled 32 27 25 21 21 21 21 
Newly 
diagnosed 
318 194 178 170 163 160 158 
Recurrence 99 39 31 28 24 22 21 
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eFigure 2f. Survival according to cancer complication at ICU admission. 
 
  
 
 
 
 
n at risk d0 d30 d60 d90 d120 d150 d180 
No cancer 
complication 
198 148 137 130 125 123 122 
Cancer 
complication 
251 112 97 89 83 80 78 
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